as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹178.02
Change
+7.17 (4.2%)
Open
₹171.73
Prev. Close
₹170.85
Day High
₹185.8
Day Low
₹169.93
Volume Analysis
Traded
1,830,502
Delivered
531,480
Delivery %
29.03%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (26.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹201.78 | ₹193.79 | ₹185.91 | ₹177.92 | ₹170.04 | ₹162.05 | ₹154.17 |
| Fibonacci | ₹193.79 | ₹187.73 | ₹183.98 | ₹177.92 | ₹171.86 | ₹168.11 | ₹162.05 |
| Camarilla | ₹182.38 | ₹180.93 | ₹179.47 | ₹177.92 | ₹176.57 | ₹175.11 | ₹173.66 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+72.1%
1 Week
-2.83%
1 Month
+10.82%
3 Months
+37.57%
6 Months
+72.32%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹37.66
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
5.56%
Net margin 16.83% × asset turnover 0.28x × equity multiplier 1.18x
Company Overview
Sector
Healthcare
Market Cap
₹1,398 Cr
P/E (TTM)
88.3
ROE
11.1%
Book Value
₹32.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Gujarat Kidney N Sup Sp L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 61/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (14/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (26.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
61/100 — AverageData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has high debtors of 172 days.
- −Working capital days have increased from 55.7 days to 91.1 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Revised FY2025-26 annual report filed; 7th AGM on 28 September 2026 with multiple shareholder resolutions.
7th AGM on 28 Sep 2026; shareholders to approve director appointments, remuneration revisions and Rs 500 crore borrowing powers.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 9 | 12 | 10 | 15 | 13 | 23 | 31 | 34 |
| Expenses + | 5 | 7 | 7 | 7 | 8 | 16 | 24 | 26 |
| Operating Profit | 5 | 5 | 3 | 9 | 5 | 7 | 6 | 8 |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.6% | 29.68% | 20.6% | 24.41% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Profit before tax | 4 | 4 | 2 | 7 | 4 | 5 | 5 | 7 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% | 23.56% |
| Net Profit + | 3 | 3 | 1 | 5 | 3 | 4 | 5 | 5 |
| EPS in Rs | 18 | 16 | 0 | 1 | 0 | 0 | 1 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 0 | 5 | 40 | 82 | 101 |
| Expenses + | 0 | 3 | 24 | 55 | 74 |
| Operating Profit | 0 | 2 | 17 | 27 | 27 |
| OPM % | — | 41.0% | 41.0% | 33.0% | 26.0% |
| Other Income + | 0 | 1 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 3 | 5 | 5 |
| Profit before tax | 0 | 2 | 13 | 21 | 21 |
| Tax % | 0.0% | 25.0% | 26.0% | 21.0% | — |
| Net Profit + | 0 | 2 | 10 | 17 | 17 |
| EPS in Rs | -1 | 86 | 2 | 2 | 2 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Reserves | 0 | 11 | 15 | 237 |
| Borrowings + | 0 | 6 | 8 | 29 |
| Other Liabilities + | 4 | 4 | 21 | 16 |
| Total Liabilities | 4 | 21 | 55 | 298 |
| Fixed Assets + | 0 | 14 | 31 | 129 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 4 | 7 | 24 | 169 |
| Total Assets | 4 | 21 | 55 | 298 |
| Equity Capital | 0 | 0 | 11 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 1 | 14 | -4 |
| Cash from Investing Activity + | 0 | 0 | -18 | -214 |
| Cash from Financing Activity + | 0 | 0 | 6 | 228 |
| Net Cash Flow | 0 | 1 | 2 | 11 |
| CFO/OP | 0 | 70 | 99 | -14 |
| Free Cash Flow | 0 | 2 | -5 | -15 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Public | 16.4% | 23.1% | 23.1% |
| Promoters | 71.45% | 71.45% | 71.45% |
| FII | 10.47% | 4.89% | 4.89% |
| DII | 1.67% | 0.56% | 0.56% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gujarat Kidney N Sup Sp L (this stock) | 1,398 | 88.3 | 5.53 | 11.1% |
| Kopran Ltd | 1,378 | 55.2 | 2.6 | 4.91% |
| Fermenta Biotech Ltd. | 1,455 | 26.6 | 3.58 | 16.4% |
| Gpt Healthcare Limited | 1,331 | 32.0 | — | 28.5% |
| Amrutajan Health Ltd | 1,480 | 72.6 | 13.76 | 20.0% |
| 3b Blackbio Dx Ltd. | 1,207 | 21.7 | 3.72 | 19.8% |
| Shalby Limited | 1,589 | 40.4 | 1.58 | 2.45% |
Which Mutual Funds Hold Gujarat Kidney N Sup Sp L?
Frequently Asked Questions about Gujarat Kidney N Sup Sp L
Gujarat Kidney N Sup Sp L (GKSL) closed at ₹178.02 on NSE on 25 September 2026, up 7.17 (4.2%) from the previous close.
Gujarat Kidney N Sup Sp L trades on the NSE (National Stock Exchange of India) under the symbol GKSL.
Gujarat Kidney N Sup Sp L has a trailing twelve-month P/E (price-to-earnings) ratio of 88.3.
Gujarat Kidney N Sup Sp L has a dividend yield of 0.0%.
Gujarat Kidney N Sup Sp L's 52-week high is ₹187.0 and its 52-week low is ₹98.2.
Gujarat Kidney N Sup Sp L has a market capitalisation of ₹1,398 crore.
Gujarat Kidney N Sup Sp L has a TopFund Quality Score of 61/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gujarat Kidney N Sup Sp L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.